| Name | TMPH |
| Description | TMPH is an inhibitor of nAChR and inhibits nAChRs lacking α5, α6, or β3 subunits. TMPH can be used in studies about nAChR dysfunction or neurological disorders. |
| In vitro | TMPH (100 nM) inhibits nAChR with an inhibition rate of 90% in Xenopus oocytes and suppresses AChR subtypes with IC50s of 1.0-390 nM[1]. |
| In vivo | In the nicotine-induced mice model, nAChR-IN-1 (20 mg/kg; s.c.) increases locomotor activity without effects on body temperature. In the tail-flick and hot-plate mice model, nAChR-IN-1(0, 0.1, 1, 5 mg/kg; s.c.) blocks the antinociceptive effect of nicotine in the hot-plate and blocks antinociception in a time-dependent manner[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Pure form: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (7.42 mM), Sonication is recommended.
DMSO : 50 mg/mL (185.58 mM), Sonication is recommended.
|
| Keywords | TMPH | tetramethylpiperidinyl heptanoate | selective inhibition | nicotinic receptor | Nicotinic acetylcholine receptors | neuronal nicotinic receptors | neurol disorder | nAChR | Inhibitor | inhibit | dysfunction | brain function | 2,2,6,6-Tetramethylpiperidin-4-yl Heptanoate |
| Inhibitors Related | Adiphenine hydrochloride | Levamisole hydrochloride | Ethyl (triphenylphosphoranylidene) acetate | Urethane | Hexamethonium Bromide | Ribavirin | Adenine | Mitotane | Choline chloride | Propoxur | N,N-Dicyclohexylcarbodiimide | Arecoline |
| Related Compound Libraries | Bioactive Compound Library | Anti-Neurodegenerative Disease Compound Library | Pain-Related Compound Library | Anti-Alzheimer's Disease Compound Library | Neuronal Signaling Compound Library | Membrane Protein-targeted Compound Library | Neurotransmitter Receptor Compound Library | Inhibitor Library | Bioactive Compounds Library Max | Ion Channel Targeted Library |
United States
